The first-in-class anti-PD-1/CTLA-4 bispecific to be recently approved for the treatment of advanced cervical cancer has been Cadonilimab (33), which is a quadrivalent bispecific with similar format to MEDI8500. This evidence concerns the gene PDCD1 and cervical carcinoma.